# Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)

> **NCT06499948** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Stefan Lujinschi** · enrollment: 34 (estimated)

## Conditions studied

- Alport Syndrome
- Thin Basement Membrane Disease
- Alport Nephropathy

## Interventions

- **DRUG:** Treatment with Spironolactone followed by Dapagliflozin followed by their combination
- **DRUG:** Treatment with Dapagliflozin followed by Spironolactone followed by their combination

## Key facts

- **NCT ID:** NCT06499948
- **Lead sponsor:** Stefan Lujinschi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-26
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-04-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06499948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06499948, "Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06499948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*